Savara, Inc. (SVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.42-2.08%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — FDA approval of Molbreevi for autoimmune PAP: FDA approval pending vs target by end-2027; RTF received May 2026.
Savara is focused on orphan lung diseases. It plans to move its headquarters by July 2026. The company increased its loan capacity to $105 million. These steps support its recovery and growth.
FDA refused to file the key drug application. This delays product approval and sales. The company is still losing money and faces risks.
The market has sold off sharply after FDA refusal news. Estimates show losses continuing. The price likely reflects these setbacks and uncertain recovery.
Breaks if: Borrowing capacity falls below $100 million
Breaks if: Relocation not completed by Q3 2026
FDA approval not granted by end of 2027
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario. SVRA is currently facing significant losses and weak financial performance, but the healthcare sector shows positive momentum that could benefit the company.
The market appears to be pricing in elevated risks due to SVRA's history of earnings misses and current financial struggles. There is a low confidence level in the company's ability to improve profitability in the near term.
Fundamentals are likely to remain weak in the near term, with increasing losses reported. The company's recent changes in leadership and operational priorities may take time to show positive results.
The thesis hinges on the company's ability to manage its elevated risk of earnings misses and the potential impact of sector performance. Positive earnings from larger healthcare companies could provide a favorable lift.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Positive data from Savara supports the FDA approval objective for molgramostim. This regulatory advancement reinforces the company's outlook. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the 1 to 3 year outlook, SVRA's performance will depend on its operational execution and sector dynamics. Not investment advice.